- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 14 Nov 23 EFFECT Notice of effectiveness
- 8 Nov 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Oct 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 28 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
18 Aug 23 S-4 Registration of securities issued in business combination transactions
- 8 Nov 23 Registration of securities issued in business combination transactions (amended)
- 18 Oct 23 Registration of securities issued in business combination transactions (amended)
- 28 Sep 23 Registration of securities issued in business combination transactions (amended)
- 18 Aug 23 Registration of securities issued in business combination transactions
Exhibit 99.6
Cory Freedland
c/o Neurogene Inc.
535 W 24th Street, 5th Floor
New York, NY 10011
Consent to Reference in Proxy Statement/Prospectus
Neoleukin Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus included in such registration statement as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement.
Sincerely, |
/s/ Cory Freedland |
Name: Cory Freedland |